Michelle is the Head of Cell and Gene Therapy at Revvity. In this role, Michelle steers the strategic direction and influences how Revvity showcases its diverse array of CGT capabilities, across products, contracted services and technology licensing, to facilitate the advancement and launch of innovative cell and gene therapies. Michelle has a PhD in mycology and a Graduate Diploma in Science and Technology Commercialization from the University of Adelaide. She was previously manager of Revvity’s base editing business and our next generation sequencing product portfolio.
